Table 1. Characteristics of 325 HIV infected children initiating antiretroviral therapy in Anantapur, India.
| NNRTI group n = 242 | LPVr group n = 83 | P-value | |
| Categorical variables | N (%) | N (%) | ?2 |
| Gender | 0.346 | ||
| Male | 134 (55.4) | 41 (49.4) | |
| Female | 108 (44.6) | 42 (50.6) | |
| Disadvantaged community | 0.738 | ||
| No | 188 (77.7) | 63 (75.9) | |
| Yes | 54 (22.3) | 20 (24.1) | |
| Living with parents | 0.064 | ||
| No | 72 (29.8) | 16 (19.3) | |
| Yes | 170 (70.2) | 67 (80.7) | |
| WHO clinical stage | 0.012 | ||
| 1–2 | 152 (62.8) | 39 (47) | |
| 3–4 | 90 (37.2) | 44 (53) | |
| Baseline viral load | 0.973 | ||
| <100,000 copies/ml | 20 (45.5) | 9 (45) | |
| >100,000 copies/ml | 24 (54.5) | 11 (55) | |
| Missing values (N) | 198 | 63 | |
| NRTIs | <0.001 | ||
| d4T+3TC | 148 (61.2) | 29 (34.9) | |
| AZT+3TC | 86 (35.5) | 52 (62.7) | |
| ABC+3TC | 8 (3.3) | 2 (2.4) | |
| Liquid formulations | <0.001 | ||
| No | 181 (74.8) | 79 (95.2) | |
| Yes | 61 (25.2) | 4 (4.8) |
3TC, lamivudine; ABC, abacavir; AZT, zidovudine; IQR, interquartile range; LPVr, lopinavir boosted with ritonavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.